Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FENNEC PHARMACEUTICALS INC.

(FENC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Fennec Pharmaceuticals : FDA Accepted Resubmission of NDA for Pedmark

06/22/2021 | 04:40am EDT

By Chris Wack

Fennec Pharmaceuticals Inc. said the U.S. Food and Drug Administration has accepted for filing the resubmission of its new-drug application for Pedmark.

The specialty pharmaceutical company said Pedmark is intended to be used for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to 18 years of age with localized, non-metastatic, solid tumors.

The Prescription Drug User Fee Act target action date has been set for Nov. 27, 2021, the company said.

Fennec said that if approved, Pedmark stands to be the first FDA-approved therapy to reduce the risk of cisplatin-induced ototoxicity in pediatric patients.

Pedmark has been granted both fast-track designation and breakthrough-therapy designation by the FDA. The complete response letter received Aug. 10, 2020, referred to deficiencies with the facility of the drug product manufacturer; no clinical safety or efficacy issues were identified and there was no requirement for further clinical data, the company said.

Fennec Pharmaceuticals shares were up 23% to $8.15 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

06-22-21 0640ET

All news about FENNEC PHARMACEUTICALS INC.
06/30FENNEC PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holder..
AQ
06/29Fennec Announces Results of Annual Meeting
GL
06/25FENNEC PHARMACEUTICALS : ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FA..
PU
06/25FENNEC PHARMACEUTICALS INC.(NASDAQCM : FENC) dropped from Russell 3000 Growth In..
CI
06/25FENNEC PHARMACEUTICALS INC.(NASDAQCM : FENC) dropped from Russell 3000E Growth I..
CI
06/25FENNEC PHARMACEUTICALS INC.(NASDAQCM : FENC) dropped from Russell 3000 Index
CI
06/25FENNEC PHARMACEUTICALS INC.(NASDAQCM : FENC) dropped from Russell 2000 Dynamic I..
CI
06/25FENNEC PHARMACEUTICALS INC.(NASDAQCM : FENC) dropped from Russell 2000 Index
CI
06/25FENNEC PHARMACEUTICALS INC.(NASDAQCM : FENC) dropped from Russell Small Cap Comp..
CI
06/25FENNEC PHARMACEUTICALS INC.(NASDAQCM : FENC) dropped from Russell Small Cap Comp..
CI
More news
Financials (USD)
Sales 2021 21,0 M - -
Net income 2021 -21,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,55x
Yield 2021 -
Capitalization 171 M 171 M -
Capi. / Sales 2021 8,13x
Capi. / Sales 2022 8,51x
Nbr of Employees 9
Free-Float 83,1%
Chart FENNEC PHARMACEUTICALS INC.
Duration : Period :
Fennec Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FENNEC PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 6,58 $
Average target price 13,40 $
Spread / Average Target 104%
EPS Revisions
Managers and Directors
Rostislav C. Raykov Chief Executive Officer & Director
Robert C. Andrade Chief Financial Officer
Khalid Islam Chairman
Chris A. Rallis Independent Director
Adrian James Haigh Independent Director
Sector and Competitors
1st jan.Capi. (M$)
FENNEC PHARMACEUTICALS INC.-11.68%192
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308